FAT1 inhibits the proliferation of DLBCL cells via increasing the m
Humans
Lymphoma, Large B-Cell, Diffuse
/ genetics
YAP-Signaling Proteins
/ metabolism
Cell Proliferation
Transcription Factors
/ metabolism
Cell Line, Tumor
RNA, Messenger
/ genetics
Adaptor Proteins, Signal Transducing
/ metabolism
Gene Expression Regulation, Neoplastic
3' Untranslated Regions
Cadherins
/ metabolism
Adenosine
/ metabolism
Signal Transduction
ALKBH5
Diffuse large B cell lymphoma (DLBCL)
FAT atypical cadherin 1 (FAT1)
Heterogeneous nuclear ribonucleoprotein D (HNRNPD)
Yes1 associated transcriptional regulator (YAP1)
m6A
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 05 2024
23 05 2024
Historique:
received:
18
01
2024
accepted:
21
05
2024
medline:
24
5
2024
pubmed:
24
5
2024
entrez:
23
5
2024
Statut:
epublish
Résumé
Emerging evidence shows that FAT atypical cadherin 1 (FAT1) mutations occur in lymphoma and are associated with poorer overall survival. Considering that diffuse large B cell lymphoma (DLBCL) is the category of lymphoma with the highest incidence rate, this study aims to explore the role of FAT1 in DLBCL. The findings demonstrate that FAT1 inhibits the proliferation of DLBCL cell lines by downregulating the expression of YAP1 rather than by altering its cellular localization. Mechanistic analysis via meRIP-qPCR/luciferase reporter assays showed that FAT1 increases the m
Identifiants
pubmed: 38782965
doi: 10.1038/s41598-024-62793-7
pii: 10.1038/s41598-024-62793-7
doi:
Substances chimiques
YAP1 protein, human
0
YAP-Signaling Proteins
0
FAT1 protein, human
0
Transcription Factors
0
RNA, Messenger
0
Adaptor Proteins, Signal Transducing
0
3' Untranslated Regions
0
Cadherins
0
N-methyladenosine
CLE6G00625
Adenosine
K72T3FS567
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11836Subventions
Organisme : People's Liberation Army The General Hospital of Western Theater Command
ID : 2021-XZYG-A08
Organisme : People's Liberation Army The General Hospital of Western Theater Command
ID : 2021-XZYG-B34
Organisme : Science and Technology Department of Sichuan Province
ID : 2023NSFSC0528
Organisme : Science and Technology Department of Sichuan Province
ID : 2022NSFSC1330
Informations de copyright
© 2024. The Author(s).
Références
Wang, Y. et al. Comparison of first-line treatments for elderly patients with diffuse large B-cell lymphoma: a systematic review and network meta-analysis. Front. Immunol. 13, 1082293 (2022).
doi: 10.3389/fimmu.2022.1082293
pubmed: 36685597
Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375–2390 (2016).
doi: 10.1182/blood-2016-01-643569
pubmed: 26980727
pmcid: 4874220
Hashmi, A. A. et al. Ki67 proliferation index in germinal and non-germinal subtypes of diffuse large B-cell lymphoma. Cureus 13, e13120 (2021).
pubmed: 33728138
pmcid: 7936471
Zaiem, F. et al. High Ki67 proliferation index but not cell-of-origin subtypes is associated with shorter overall survival in diffuse large B-cell lymphoma. Avicenna J. Med. 10, 241–248 (2020).
doi: 10.4103/ajm.ajm_81_20
pubmed: 33437697
pmcid: 7791286
Liu, Y. & Barta, S. K. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am. J. Hematol. 94, 604–616 (2019).
doi: 10.1002/ajh.25460
pubmed: 30859597
Pastushenko, I. et al. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature 589, 448–455 (2021).
doi: 10.1038/s41586-020-03046-1
pubmed: 33328637
Lan, T. et al. FAT1 upregulates in oral squamous cell carcinoma and promotes cell proliferation via cell cycle and DNA repair. Front. Oncol. 12, 870055 (2022).
doi: 10.3389/fonc.2022.870055
pubmed: 35646625
pmcid: 9130556
Kim, S. I. et al. Clinical significance of FAT1 gene mutation and mRNA expression in patients with head and neck squamous cell carcinoma. Mol. Oncol. 16, 1661–1679 (2022).
doi: 10.1002/1878-0261.13171
pubmed: 34939311
pmcid: 9019907
Li, M., Zhong, Y. & Wang, M. Fat1 suppresses the tumor-initiating ability of nonsmall cell lung cancer cells by promoting yes-associated protein 1 nuclear-cytoplasmic translocation. Environ. Toxicol. 36, 2333–2341 (2021).
doi: 10.1002/tox.23347
pubmed: 34390292
Pileri, P. et al. FAT1: a potential target for monoclonal antibody therapy in colon cancer. Br. J. Cancer 115, 40–51 (2016).
doi: 10.1038/bjc.2016.145
pubmed: 27328312
pmcid: 4931367
Wojtalewicz, N. et al. A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding. PLOS ONE 9, e90461 (2014).
doi: 10.1371/journal.pone.0090461
pubmed: 24625754
pmcid: 3953070
Li, Z. et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway. Cancer Cell 34, 893–905 (2018).
doi: 10.1016/j.ccell.2018.11.006
pubmed: 30537512
pmcid: 6294301
He, C. K. et al. LncRNA FGD5-AS1 enhances the proliferation and stemness of hepatocellular carcinoma cells through targeting miR-223 and regulating the expression of ECT2 and FAT1. Hepatol. Res. 52, 614–629 (2022).
doi: 10.1111/hepr.13767
pubmed: 35366388
Chen, M. et al. FAT1 inhibits the proliferation and metastasis of cervical cancer cells by binding β-catenin. Int. J. Clin. Exp. Pathol. 12, 3807–3818 (2019).
pubmed: 31933769
pmcid: 6949748
Madan, E. et al. FAT1 is a novel upstream regulator of HIF1α and invasion of high grade glioma. Int. J. Cancer 139, 2570–2582 (2016).
doi: 10.1002/ijc.30386
pubmed: 27536856
pmcid: 6585695
Zhao, A. et al. Analysis of genetic alterations in ocular adnexal mucosa-associated lymphoid tissue lymphoma with whole-exome sequencing. Front. Oncol. 12, 817635 (2022).
doi: 10.3389/fonc.2022.817635
pubmed: 35359413
pmcid: 8962736
Laginestra, M. A. et al. Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. Mod. Pathol. 33, 179–187 (2020).
doi: 10.1038/s41379-019-0279-8
pubmed: 31028364
Fabretti, F. et al. Expanding the spectrum of FAT1 nephropathies by novel mutations that affect hippo signaling. Kidney Int. Rep. 6, 1368–1378 (2021).
doi: 10.1016/j.ekir.2021.01.023
pubmed: 34013115
pmcid: 8116753
Jiang, S. et al. S100A14 inhibits cell growth and epithelial-mesenchymal transition (EMT) in prostate cancer through FAT1-mediated Hippo signaling pathway. Hum. Cell 34, 1215–1226 (2021).
doi: 10.1007/s13577-021-00538-8
pubmed: 33890248
Lu, Y. et al. FAT1 and PTPN14 regulate the malignant progression and chemotherapy resistance of Esophageal cancer through the hippo Signaling pathway. Anal. Cell. Pathol. 2021, 9290372 (2021).
doi: 10.1155/2021/9290372
Zhou, X. et al. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the Tumorigenesis of diffuse large B-cell lymphoma. J. Hematol. Oncol. 13, 77 (2020).
doi: 10.1186/s13045-020-00906-1
pubmed: 32546241
pmcid: 7298789
Wang, Z. et al. GPNMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt/β-catenin signaling pathway. Arch. Biochem. Biophys. 710, 108998 (2021).
doi: 10.1016/j.abb.2021.108998
pubmed: 34280359
Martin, D. et al. Assembly and activation of the Hippo signalome by FAT1 tumor suppressor. Nat. Commun. 9, 2372 (2018).
doi: 10.1038/s41467-018-04590-1
pubmed: 29985391
pmcid: 6037762
Liebig, S. et al. FAT1 expression in T-cell acute lymphoblastic leukemia (T-ALL) modulates proliferation and WNT signaling. Sci. Rep. 13, 972 (2023).
doi: 10.1038/s41598-023-27792-0
pubmed: 36653435
pmcid: 9849452
Peng, Z., Gong, Y. & Liang, X. Role of FAT1 in health and disease. Oncol. Lett. 21, 398 (2021).
doi: 10.3892/ol.2021.12659
pubmed: 33777221
pmcid: 7988705
Irshad, K. et al. Upregulation of atypical cadherin FAT1 promotes an immunosuppressive tumor microenvironment via TGF-β. Front. Immunol. 13, 813888 (2022).
doi: 10.3389/fimmu.2022.813888
pubmed: 35720420
pmcid: 9205206
Ahmed, A. F. et al. FAT1 cadherin acts upstream of Hippo signalling through TAZ to regulate neuronal differentiation. Cell. Mol. Life Sci. 72, 4653–4669 (2015).
doi: 10.1007/s00018-015-1955-6
pubmed: 26104008
Colak, S. & Ten Dijke, P. Targeting TGF-β signaling in cancer. Trends Cancer 3, 56–71 (2017).
doi: 10.1016/j.trecan.2016.11.008
pubmed: 28718426
Peng, D., Fu, M., Wang, M., Wei, Y. & Wei, X. Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol. Cancer 21, 104 (2022).
doi: 10.1186/s12943-022-01569-x
pubmed: 35461253
pmcid: 9033932
Stelling, A. et al. Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma. Blood Adv. 3, 3020–3032 (2019).
doi: 10.1182/bloodadvances.2019000210
pubmed: 31648327
pmcid: 6849946
Wu, H., Sun, H. C. & Ouyang, G. F. T-cell immunoglobulin mucin molecule-3, transformation growth factor β, and chemokine-12 and the prognostic status of diffuse large B-cell lymphoma. World J. Clin. Cases 10, 11804–11811 (2022).
doi: 10.12998/wjcc.v10.i32.11804
pubmed: 36405294
pmcid: 9669877
Chen, Y. et al. CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression. Open Life Sci. 16, 909–919 (2021).
doi: 10.1515/biol-2021-0094
pubmed: 34553071
pmcid: 8422981
Xu, P. P. et al. JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide. Sci. Rep. 7, 7433 (2017).
doi: 10.1038/s41598-017-07964-5
pubmed: 28785100
pmcid: 5547054
Zhou, Y., Zeng, P., Li, Y. H., Zhang, Z. & Cui, Q. SRAMP: prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features. Nucleic Acids Res. 44, e91 (2016).
doi: 10.1093/nar/gkw104
pubmed: 26896799
pmcid: 4889921
Chen, J., Fang, Y., Xu, Y. & Sun, H. Role of m6A modification in female infertility and reproductive system diseases. Int. J. Biol. Sci. 18, 3592–3604 (2022).
doi: 10.7150/ijbs.69771
pubmed: 35813486
pmcid: 9254474
Song, W. et al. ALKBH5-mediated N(6)-methyladenosine modification of TRERNA1 promotes DLBCL proliferation via p21 downregulation. Cell Death Discov. 8, 25 (2022).
doi: 10.1038/s41420-022-00819-7
pubmed: 35031597
pmcid: 8760254
Zhang, X. et al. Clinical and prognostic pan-cancer analysis of N6-methyladenosine regulators in two types of hematological malignancies: a retrospective study based on TCGA and GTEx databases. Front. Oncol. 11, 623170 (2021).
doi: 10.3389/fonc.2021.623170
pubmed: 33816257
pmcid: 8015800
Zhang, N. et al. HSF1 upregulates ATG4B expression and enhances epirubicin-induced protective autophagy in hepatocellular carcinoma cells. Cancer Lett. 409, 81–90 (2017).
doi: 10.1016/j.canlet.2017.08.039
pubmed: 28889000
Zhang, N. et al. MiR-449a attenuates autophagy of T-cell lymphoma cells by downregulating ATG4B expression. BMB Rep. 53, 254–259 (2020).
doi: 10.5483/BMBRep.2020.53.5.219
pubmed: 32172731
pmcid: 7262515
Dominissini, D., Moshitch-Moshkovitz, S., Salmon-Divon, M., Amariglio, N. & Rechavi, G. Transcriptome-wide mapping of N(6)-methyladenosine by m(6)A-seq based on immunocapturing and massively parallel sequencing. Nat. Protoc. 8, 176–189 (2013).
doi: 10.1038/nprot.2012.148
pubmed: 23288318